Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

about

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.

P2860

Q54960911-BAE34BAC-443A-4A46-BE3C-433A3C57AEAE

P2860

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Item

http://www.wikidata.org/entity/Q38735120

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

@en

type

Item

label

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

@en

prefLabel

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

@en

P1476

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

@en

P2093

Clotilde Descarpentries

http://www.w3.org/2001/XMLSchema#string

Zoulika Kherrouche

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

Met, metastasis, motility and more

P31

scholarly article

P356

10.1093/JNCI/DJW262

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28376232

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

about

P2860

P2860

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P921